Reata Pharmaceuticals

Reata Pharmaceuticals, Inc. is a pharmaceutical company based in Plano, Texas. Founded in 2002, it is primarily focused on investigating experimental oral antioxidative and anti-inflammatory drugs,[2] which dually activate the antioxidative transcription factor Nrf2 and inhibit the pro-inflammatory transcription factor NF-κB.[3] The last CEO of Reata Pharmaceuticals was J. Warren Huff.

In July 2023, it was announced Reata had been acquired by the Cambridge, Massachusetts-headquartered multinational biotechnology company, Biogen for nearly $6.5 billion.[4] The purchase was completed on September 26 and Reata stock was delisted from the Nasdaq.[5]

Pipeline

Bardoxolone Methyl

Bardoxolone methyl was one of the first of the class of synthetic triterpenoids to be studied in the clinic. It has been evaluated in Phase 1 studies for cancer,[6] Phase 2 and 3 studies for chronic kidney disease (CKD) associated with type 2 diabetes,[7][8] and is currently being evaluated in a Phase 2 study for pulmonary arterial hypertension.[9][10][11]

RTA 408

Omaveloxolone (RTA 408) is a second generation member of the synthetic oleanane triterpenoid compounds. The FDA approved Skyclarys (omoveloxolone) in 2023 for the treatment of Friedreich’s ataxia (FA), a hereditary neurological disorder that strikes during adolescence and leaves patients unable to walk and often cuts short their lives. Skyclarys was also approved in the European Union, Canada, the UK, and Brazil in April 2025.

Skyclarys become the first drug approved for the condition, which affects roughly 5,000 who have been diagnosed in the United States and 22,000 worldwide. Preclinical studies demonstrated that RTA 408 possesses antioxidative and anti-inflammatory activities,[12][13] as well as the potential to improve mitochondrial bioenergetics.[14] Because of the broad applicability of such effects across many diseases, RTA 408 is currently under clinical investigation in several Phase 2 clinical studies including immunooncology,[15] corneal endothelial cell loss associated with cataract surgery[16] Friedreich’s ataxia,[17] and mitochondrial myopathies.[18]

Others

Reata was also actively engaged in the discovery of small molecule disease-modifying drugs that function by stabilizing the normal three-dimensional structure of target proteins or generally enhancing the folding environment of the cell. Defects in protein folding underlie a large number of genetic diseases including certain forms of cancer, familial Alzheimer's disease, and cystic fibrosis. Protein folding defects are also believed to play important roles in the development of non-inherited forms of many of these diseases.

industry	Biotechnology
fate	Acquired by Biogen
revenue	US $26.52 million (2019) US $53.59 million (2018)‡R1R‡
owner	Biogen (2023–present)
website	https://www.reatapharma.com

Reata Pharmaceuticals

Pipeline

Bardoxolone Methyl

RTA 408

Others

Partnerships

External links

References